Research and Markets: Pancreatic Ductal Adenocarcinoma Pipeline Insights ...
Pancreatic Ductal Adenocarcinoma- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Pancreatic Ductal Adenocarcinoma. The main objective of this report to track competitor pipeline molecules, related research activities ...
Business Wire (press release) - Fri, 12 Jun 2015 06:18



Prevalence of germline BRCA mutations 5% in patients with pancreatic ...
Germline BRCA1/2 mutations have been associated with an increased risk for pancreatic ductal adenocarcinoma, but data on the prevalence of BRCA1 mutations in these patients are lacking, according to study background. Identification of BRCA mutations ...
Healio - Mon, 08 Jun 2015 14:36



FDA to Review NDA for Metastatic Pancreatic Adenocarcinoma Therapy
Merrimack Pharmaceuticals and Baxalta announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for irinotecan liposome injection (MM-398) for the treatment of patients with metastatic ...
Monthly Prescribing Reference (registration) - Thu, 25 Jun 2015 07:26

U.S. FDA Grants Priority Review for MM-398 New Drug Application
PR Newswire (press release) - Thu, 25 Jun 2015 04:03

FDA Grants Priority Review To MM-398 in Pancreatic Cancer
The Cancer Letter Publications - Fri, 26 Jun 2015 12:18



GERD Duration, Other Factors Raise Esophageal Adenocarcinoma Risk
Symptomatic gastroesophageal reflux disease (sGERD) and other factors increase the risk of esophageal adenocarcinoma exponentially with exposure duration, a recent study published online ahead of print in the journal Cancer Epidemiology, Biomarkers ...
Cancer Therapy Advisor - Fri, 12 Jun 2015 08:21



Patients with Lung Adenocarcinoma, Exon20ins May Not Respond to TKI Therapy
Many patients with advanced lung adenocarcinoma who have EGFR exon20ins may not respond to EGFR tyrosine kinase inhibitors (TKI) therapy, according to a recent study published online ahead of print in Cancer. Researchers led by Jarushka Naidoo, ...
Cancer Therapy Advisor - Fri, 12 Jun 2015 06:52



EGFR Mutations Most Prevalent in Women with Adenocarcinoma, No Smoking ...
Results showed that of 431 patients who had EGFR mutations, females (OR= 1.85; 95% CI: 1.48, 2.32) with adenocarcinoma (OR= 2.94; 95% CI: 2.17, 4.08) who had never smoked (OR= 3.64; 95% CI: 2.91, 4.56) showed correlation with EGFR mutation status ...
Cancer Therapy Advisor - Mon, 15 Jun 2015 08:11



YAP1 R331W Mutation is Predisposition for Lung Adenocarcinoma
YAP1 R331W is an allele predisposed for lung adenocarcinoma with high familial penetrance, a new study published online ahead of print in the Journal of Clinical Oncology has shown. For the study, researchers performed whole-genome sequencing for a ...
Cancer Therapy Advisor - Wed, 10 Jun 2015 08:13



Simple Clinical, Laboratory Parameters Predict Mortality in Pancreatic ...
Sohal, D. P.S., Shrotriya, S., Glass, K. T., Pelley, R. J., McNamara, M. J., Estfan, B., Shapiro, M., Wey, J., Chalikonda, S., Morris-Stiff, G., Walsh, R. M. and Khorana, A. A. (2015), Predicting early mortality in resectable pancreatic adenocarcinoma ...
Cancer Therapy Advisor - Mon, 22 Jun 2015 06:17


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014